Screener
Aclaris Therapeutics ACRS Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current liabilities | 2,790 | 2,753 |
| Total current liabilities | 28,241 | 28,645 |
| Other liabilities | 1,262 | 1,565 |
| Deferred income, net of current portion | 14,309 | 16,168 |
| Contingent consideration | 11,300 | 11,000 |
| Total liabilities | 55,112 | 57,378 |
| Stockholders’ Equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's contract liabilities, non-current?
- Aclaris Therapeutics (ACRS) reported contract liabilities, non-current of $14.31M in Q2 2026.
- How has Aclaris Therapeutics's contract liabilities, non-current changed year-over-year?
- Aclaris Therapeutics's contract liabilities, non-current decreased by 21.5% year-over-year, from $18.22M to $14.31M.
- What does contract liabilities, non-current mean?
- Obligation to transfer goods or services for which payment has been received, expected to be satisfied beyond one year.
Ask your AI about Aclaris Therapeutics's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude